- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Differentiated thyroid cancer (DTC)
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 430KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 95KB)
Cabozantinib – March 2024
Cabozantinib (DTC): Tablet 20 mg, Tablet 40 mg, Tablet 60 mg; Cabometyx®
Last updated
30 May 2025